Sanofi expects FDA decision on Lemtrada in H2 2013

PARIS Mon Jan 28, 2013 1:10am EST

PARIS Jan 28 (Reuters) - Sanofi expects the U.S. Food and Drug Administration to rule on its application for a new multiple sclerosis treatment called Lemtrada by the second half of this year.

In a statement, the French drug maker added that a scientific advisory panel was expected to meet in the second quarter to examine the application.

The drug, which was developed by Sanofi subsidiary Genzyme, has already been submitted for review by the European Medecines Agency.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.